Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Mullerian Hormone | 5 | 2020 | 59 | 1.780 |
Why?
|
| Ovary | 4 | 2020 | 688 | 1.260 |
Why?
|
| Polyps | 2 | 2021 | 71 | 0.940 |
Why?
|
| Ovulation Induction | 1 | 2024 | 66 | 0.910 |
Why?
|
| Hysteroscopy | 2 | 2021 | 47 | 0.880 |
Why?
|
| Fertilization in Vitro | 1 | 2024 | 207 | 0.830 |
Why?
|
| Ultrasonography | 5 | 2024 | 1928 | 0.800 |
Why?
|
| Sodium Chloride | 1 | 2021 | 159 | 0.760 |
Why?
|
| Uterus | 2 | 2024 | 798 | 0.680 |
Why?
|
| Fallopian Tubes | 1 | 2020 | 128 | 0.680 |
Why?
|
| Genes, BRCA2 | 1 | 2020 | 321 | 0.620 |
Why?
|
| Genes, BRCA1 | 1 | 2020 | 396 | 0.600 |
Why?
|
| Ovarian Follicle | 1 | 2018 | 140 | 0.580 |
Why?
|
| Heterografts | 1 | 2018 | 739 | 0.520 |
Why?
|
| RNA, Messenger | 2 | 2020 | 6368 | 0.380 |
Why?
|
| Pregnancy Trimester, First | 3 | 2020 | 126 | 0.360 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 4118 | 0.350 |
Why?
|
| Yolk Sac | 2 | 2020 | 26 | 0.350 |
Why?
|
| Abortion, Spontaneous | 2 | 2021 | 107 | 0.330 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2008 | 22 | 0.310 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2008 | 73 | 0.290 |
Why?
|
| Pregnancy | 7 | 2024 | 8107 | 0.260 |
Why?
|
| Bartter Syndrome | 1 | 2005 | 4 | 0.250 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2020 | 922 | 0.230 |
Why?
|
| Embryo Transfer | 1 | 2024 | 89 | 0.230 |
Why?
|
| Pregnancy Outcome | 2 | 2020 | 682 | 0.220 |
Why?
|
| Pilot Projects | 5 | 2021 | 2843 | 0.220 |
Why?
|
| Vitrification | 2 | 2019 | 6 | 0.200 |
Why?
|
| Insulins | 1 | 2021 | 19 | 0.190 |
Why?
|
| Receptors, Peptide | 2 | 2020 | 87 | 0.190 |
Why?
|
| Endometrium | 2 | 2021 | 460 | 0.190 |
Why?
|
| Peritoneal Cavity | 1 | 2020 | 58 | 0.180 |
Why?
|
| Suction | 1 | 2020 | 121 | 0.180 |
Why?
|
| Pressure | 1 | 2020 | 187 | 0.180 |
Why?
|
| Gestational Sac | 1 | 2020 | 2 | 0.180 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2020 | 223 | 0.180 |
Why?
|
| Female | 16 | 2024 | 148486 | 0.170 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 559 | 0.170 |
Why?
|
| Granulosa Cells | 1 | 2020 | 153 | 0.170 |
Why?
|
| Urogenital Abnormalities | 1 | 2021 | 174 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2010 | 1900 | 0.160 |
Why?
|
| Cell Dedifferentiation | 1 | 2019 | 99 | 0.160 |
Why?
|
| Nanog Homeobox Protein | 1 | 2018 | 61 | 0.160 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2018 | 105 | 0.150 |
Why?
|
| Receptors, Pituitary Hormone | 1 | 2017 | 3 | 0.150 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2018 | 119 | 0.150 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2018 | 224 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 3023 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2018 | 369 | 0.140 |
Why?
|
| Analysis of Variance | 1 | 2020 | 2316 | 0.130 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 1054 | 0.130 |
Why?
|
| Apoptosis | 2 | 2020 | 7741 | 0.120 |
Why?
|
| Estradiol | 1 | 2018 | 828 | 0.120 |
Why?
|
| Placenta | 1 | 2019 | 561 | 0.120 |
Why?
|
| Humans | 16 | 2024 | 270033 | 0.120 |
Why?
|
| Adult | 8 | 2024 | 81689 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2024 | 9464 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2020 | 4329 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2020 | 13378 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 5153 | 0.110 |
Why?
|
| Logistic Models | 1 | 2020 | 3438 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 1503 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 10382 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2024 | 39736 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2020 | 1301 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 7883 | 0.090 |
Why?
|
| Receptors, FSH | 2 | 2020 | 19 | 0.080 |
Why?
|
| Inhibins | 2 | 2020 | 116 | 0.080 |
Why?
|
| Mice | 2 | 2020 | 35465 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2020 | 7236 | 0.070 |
Why?
|
| Animals | 2 | 2020 | 61714 | 0.060 |
Why?
|
| Potassium | 1 | 2005 | 330 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2005 | 358 | 0.050 |
Why?
|
| Gestational Age | 1 | 2005 | 1172 | 0.050 |
Why?
|
| Oocyte Retrieval | 1 | 2020 | 8 | 0.050 |
Why?
|
| Follicular Fluid | 1 | 2020 | 11 | 0.050 |
Why?
|
| Adolescent | 1 | 2020 | 32647 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2021 | 675 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2020 | 472 | 0.040 |
Why?
|
| Pregnancy, Multiple | 1 | 2019 | 49 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 689 | 0.040 |
Why?
|
| Receptors, LH | 1 | 2017 | 15 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 9040 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2019 | 286 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 1130 | 0.040 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 72 | 0.040 |
Why?
|
| Premenopause | 1 | 2017 | 138 | 0.040 |
Why?
|
| Nomograms | 1 | 2019 | 312 | 0.040 |
Why?
|
| Counseling | 1 | 2020 | 381 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2017 | 351 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2021 | 1603 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 1542 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 4360 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 2158 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2005 | 6752 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 5806 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 15172 | 0.020 |
Why?
|
| Prognosis | 1 | 2020 | 22451 | 0.010 |
Why?
|
PEREGRIN-ALVAREZ's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(98)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(3)
People in Profiles who have published with this person.
Explore
_
Similar People
(58)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_